Connect with us


Increase in Fetal Chromosomal Abnormalities Drives Growth



DUBLIN, May 24, 2023 /PRNewswire/ — The “Carrier Screening Global Market Report 2023” report has been added to’s offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the market.

The global carrier screening market is expected to grow from $2.03 billion in 2022 to $2.38 billion in 2023 at a compound annual growth rate (CAGR) of 17.0%. The carrier screening market is expected to grow to $4.30 billion in 2027 at a CAGR of 15.9%.

Major players in the carrier screening market are Invitae Corporation, Fulgent Genetics Inc., Illumina Inc., Sema4 Holdings Corporation, Natera Inc., Laboratory Corporation of America Holdings, Centogene NV, Thermo Fisher Scientific Inc., Myriad Genetics Inc., Eurofins Scientific SE, OPKO Health Inc., Quest Diagnostics Inc., Luminex Corporation, BGI Genomics, Gene by Gene, OME Care, MedGenome Inc., and Otogenetics Corporation.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the RussiaUkraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Carrier screening refers to a type of genetic test that can determine if there is a gene that causes certain genetic illnesses. The carrier screening is used to identify people who have one copy of a gene mutation that produces a hereditary illness when two copies are present.

The main types of carrier screening are expanded carrier screening and targeted disease carrier screening. Expanded carrier screening provides carrier screening for multiple autosomal and X-linked recessive disorders, facilitated by new genetic testing technologies, and allows testing of individuals regardless of ancestry or geographic origin. The products and services are service and product.

The medical conditions are pulmonary conditions, hematological conditions, neurological conditions, and other medical conditions. The technologies involved DNA sequencing, polymerase chain reaction, microarrays, and other technologies. The various end users included hospitals, reference laboratories, physician offices and clinics, and other end users.

Technological advancements are a key trend gaining popularity in the carrier screening market. Major companies operating in the carrier screening market are focused on developing new technological solutions to strengthen their position. For instance, in July 2020, NIPD Genetics, a Cyprus-based biotechnology company, released Adventia, a broader carrier screening test for anyone or a couple interested in learning if they are a carrier of a genetic disease. Adventia is a safe, reliable, and exclusive test for up to 229 X-linked and autosomal recessive illnesses that offer healthcare professionals and individuals significant genetic insight and information about their reproductive possibilities.

Adventia consists of three panels: (a) Focus Panels, which give the option to test one of six moderate-to-severe, high-frequency monogenic diseases; (b) the Guidelines-Based Panel, which includes all diseases in the Focus Panels and tests for 19 diseases with high carrier frequency; and (c) the Comprehensive Panel, which includes all diseases in the Guidelines-Based Panel and tests for a total of 229 diseases with a clearly defined phenotype and high cumulative frequency.

In May 2022, Sema4 OpCo Inc., a US-based firm providing patient-focused health intelligence, acquired GeneDx LLC for $623 million. The acquisition is expected to establish Sema4 as one of the biggest and most sophisticated genomic testing companies in the United States and increase its health information database, which will alter patient care and advance therapeutic research. GeneDx LLC is a US-based company operating in analysis for rare disorders and genomic testing.

North America was the largest region in the carrier screening market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carrier screening report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the carrier screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

An increase in fetal chromosomal abnormalities and genetic disorders is expected to propel the growth of the carrier screening market going forward. Fetal chromosomal abnormalities refer to a fetus with an abnormal number of chromosomes, an abnormal quantity of DNA inside a chromosome. Prenatal testing for chromosomal abnormalities is intended to provide an accurate assessment of a patient’s risk of carrying a fetus with a chromosomal disorder.

For instance, in February 2022, according to estimates by the World Health Organization, a Switzerland-based global health agency, birth defects cause 240 000 newborns to pass away in the first 28 days of life each year. An additional 170,000 children between the ages of 1 month and 5 years die as a result of birth defects.

Moreover, in March 2022, according to an article published by the Government of United Nations, Down syndrome is estimated to affect 1 in 1,000 to 1 in 1,100 live births worldwide. Every year, between 3,000 and 5,000 children are born with this chromosome disorder. Therefore, an increase in fetal chromosomal abnormalities and genetic disorders is driving the growth of the carrier screening market.

The carrier screening market includes revenues earned by entities by providing customized panel testing and predesigned panel testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Key Topics Covered:

1. Executive Summary

2. Carrier Screening Market Characteristics

3. Carrier Screening Market Trends And Strategies

4. Carrier Screening Market – Macro Economic Scenario
4.1. COVID-19 Impact On Carrier Screening Market
4.2. Ukraine-Russia War Impact On Carrier Screening Market
4.3. Impact Of High Inflation On Carrier Screening Market

5. Carrier Screening Market Size And Growth
5.1. Global Carrier Screening Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Carrier Screening Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Carrier Screening Market Segmentation
6.1. Global Carrier Screening Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Expanded Carrier Screening
  • Targeted Disease Carrier Screening

6.2. Global Carrier Screening Market, Segmentation By Product And Service, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

6.3. Global Carrier Screening Market, Segmentation By Medical Condition, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Pulmonary Conditions
  • Hematological Conditions
  • Neurological Conditions
  • Other Medical Conditions

6.4. Global Carrier Screening Market, Segmentation By Technology, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • DNA Sequencing
  • Polymerase Chain Reaction
  • Microarrays
  • Other Technologies

6.5. Global Carrier Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Hospitals
  • Reference Laboratories
  • Physician Offices and Clinics
  • Other End Users

7. Carrier Screening Market Regional And Country Analysis
7.1. Global Carrier Screening Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Carrier Screening Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716 


SOURCE Research and Markets

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *